Laroche M, Mazières B
Baillieres Clin Rheumatol. 1991 Apr;5(1):61-76. doi: 10.1016/s0950-3579(05)80296-1.
Fluoride stimulates bone formation and is used in the treatment of vertebral osteoporosis. Epidemiological and experimental studies have shown that fluoride bone is denser but not always stronger than normal bone, and the main side-effects attributed to this drug involve bone tissue. True fractures, with cortical rupture, are few (near 5%); their rate seems to correspond to that generally found in osteoporotic patients without treatment. On the other hand, stress fractures and arthralgia of the lower limbs are much more frequent (near 30%), but they often follow a benign course. Digestive tolerance of fluoride is now good, improved by the introduction of gastro-resistant industrial galenicals. However, the question of whether the risk/benefit ratio is positive is always under discussion.
氟化物可刺激骨形成，用于治疗椎体骨质疏松症。流行病学和实验研究表明，氟化物治疗后的骨骼密度更高，但并不总是比正常骨骼更强壮，且该药物的主要副作用涉及骨组织。真正伴有皮质破裂的骨折较少见（接近5%）；其发生率似乎与未经治疗的骨质疏松症患者的一般发生率相当。另一方面，应力性骨折和下肢关节痛更为常见（接近30%），但通常病程良性。目前氟化物的消化耐受性良好，随着胃内滞留型制剂的引入，耐受性有所改善。然而，其风险/效益比是否为正的问题仍在讨论中。
